Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of angelman syndrome mice impairs motor function

Journal of Neuroscience

Volumn 35, Issue 11, 2015, Pages 4706-4718

  Sun, Jiandong ^a   Liu, Yan ^a   Moreno, Stephanie ^a   Baudry, Michel ^a   Bi, Xiaoning ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Angelman syndrome; mTOR; Phosphorylation; Purkinje neuron; Rictor; TSC2

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; S6 KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CATWALK GAIT ANALYSIS TEST; CEREBELLUM; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; HAPPY PUPPET SYNDROME; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NEUROPHYSIOLOGY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PURKINJE CELL; QUANTITATIVE ASSAY; ROTAROD TEST; SIGNAL TRANSDUCTION; SYNAPTIC POTENTIAL; WESTERN BLOTTING; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANGELMAN SYNDROME; ANIMALS; CEREBELLUM; MALE; MICE; MICE, TRANSGENIC; MOTOR SKILLS; MULTIPROTEIN COMPLEXES; TOR SERINE-THREONINE KINASES;

EID: 84925047891     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4276-14.2015     Document Type: Article

References (56)

1. Barry RJ, Leitner RP, Clarke AR, Einfeld SL (2005) Behavioral aspects of Angelman syndrome: a case control study. AmJ Med Genet A 132A:8-12.CrossRef Medline.
2. Baudry M, Kramar E, Xu X, Zadran H, Moreno S, Lynch G, Gall C, Bi X (2012) Ampakines promote spine actin polymerization, long-term potentiation,and learning in a mouse model of Angelman syndrome. Neurobiol Dis 47:210-215. CrossRef Medline.
3. Cao C, Rioult-Pedotti MS, Migani P, Yu CJ, Tiwari R, Parang K, Spaller MR, Goebel DJ, Marshall J (2013) Impairment of TrkB-PSD-95 signaling in Angelman syndrome. PLoS Biol 11:e1001478. CrossRef Medline.
4. Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S, Perreault C, Roux PP, Kitano H (2010) A comprehensive map of the mTOR signaling network. Mol Syst Biol 6:453. CrossRef Medline.
5. Chamberlain SJ, Chen PF, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, Levine ES, Lalande M (2010) Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci U S A 107:17668-17673. CrossRef Medline.
6. Chen Q, Peto CA, Shelton GD, Mizisin A, Sawchenko PE, Schubert D (2009) Loss of modifier of cell adhesion reveals a pathway leading to axonal degeneration. J Neurosci 29:118-130. CrossRef Medline.
7. Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem280:25485–25490. CrossRef Medline.
8. Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69:1821–1827.CrossRef Medline.
9. Dan B (2009) Angelman syndrome: current understanding and research prospects. Epilepsia 50:2331–2339. CrossRef Medline.
10. D’Angelo E (2014) The organization of plasticity in the cerebellar cortex: from synapses to control. Prog Brain Res 210:31–58. CrossRef Medline.
11. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL (2008) The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 17:111–118. CrossRef Medline.
12. Ehninger D, Silva AJ (2011) Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med 17:78–87. CrossRef Medline.
13. Gao Z, van Beugen BJ, De Zeeuw CI (2012) Distributed synergistic plasticity and cerebellar learning. Nat Rev Neurosci 13:619–635. CrossRef Medline.
14. García-Martinez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375–385. CrossRef Medline.
15. Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Griffith EC, Waldon Z, Maehr R, Ploegh HL, Chowdhury S, Worley PF, Steen J, Greenberg ME (2010) The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell140:704-716. CrossRef Medline.
16. Guffanti G, Strik Lievers L, Bonati MT, Marchi M, Geronazzo L, Nardocci N, Estienne M, Larizza L, Macciardi F, Russo S (2011) Role of UBE3A and ATP10A genes in autism susceptibility region 15q11–q13 in an Italian population: a positive replication for UBE3A. Psychiatry Res 185:33–38.CrossRef Medline.
17. Gustin RM, Bichell TJ, Bubser M, Daily J, Filonova I, Mrelashvili D, Deutch AY, Colbran RJ, Weeber EJ, Haas KF (2010) Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome. Neurobiol Dis 39:283–291. CrossRef Medline.
18. Heck DH, Zhao Y, Roy S, LeDoux MS, Reiter LT (2008) Analysis of cerebellar function in Ube3a-deficient mice reveals novel genotype-specific behaviors. Hum Mol Genet 17:2181–2189. CrossRef Medline.
19. Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity,memory and disease. Trends Neurosci 33:67–75. CrossRef Medline.
20. Huang HS, Burns AJ, Nonneman RJ, Baker LK, Riddick NV, Nikolova VD, Riday TT, Yashiro K, Philpot BD, Moy SS (2013) Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res 243:79-90. CrossRef Medline.
21. Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179-190. CrossRef Medline.
22. Huang J, Dibble CC, Matsuzaki M, Manning BD (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol CellBiol 28:4104–4115. CrossRef Medline.
23. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657. CrossRef Medline.
24. Jacinto E, Loewith R, Schmidt A, Lin S, Ru¨egg MA, Hall A, Hall MN (2004)Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128. CrossRef Medline.
25. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, Sweatt JD, Beaudet AL (1998) Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21:799–811. CrossRef Medline.
26. Julien LA, Carriere A, Moreau J, Roux PP (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30:908-921. CrossRef Medline.
27. Kaphzan H, Hernandez P, Jung JI, Cowansage KK, Deinhardt K, Chao MV, Abel T, Klann E (2012) Reversal of impaired hippocampal long-term potentiation and contextual fear memory deficits in Angelman syndrome model mice by ErbB inhibitors. Biol Psychiat 72:182–190. CrossRef Medline.
28. Kaphzan H, Buffington SA, Ramaraj AB, Lingrel JB, Rasband MN, Santini E, Klann E (2013) Genetic reduction of the alpha1 subunit of Na/KATPase corrects multiple hippocampal phenotypes in Angelman syndrome. Cell Rep 4:405-412. CrossRef Medline.
29. Kishino T, Lalande M, Wagstaff J (1997) UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15:70-73. CrossRef Medline.
30. Lalande M, Calciano MA (2007) Molecular epigenetics of Angelman syndrome. Cell Mol Life Sci 64:947–960. CrossRef Medline.
31. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293. CrossRef Medline.
32. Lee KJ, Jung JG, Arii T, Imoto K, Rhyu IJ (2007) Morphological changes in dendritic spines of Purkinje cells associated with motor learning. Neurobiol Learn Mem 88:445– 450. CrossRef Medline.
33. Liu P, Guo J, Gan W, Wei W (2014) Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. Protein Cell 5:171–177. CrossRef Medline.
34. Manning BD (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167:399–403. CrossRef Medline.
35. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell10:151–162. CrossRef Medline.
36. Margolis SS, Salogiannis J, Lipton DM, Mandel-Brehm C, Wills ZP, Mardinly AR, HuLGreer PL, Bikoff JB, Ho HY, Soskis MJ, Sahin M, Greenberg ME (2010) EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 143:442-455.CrossRef Medline.
37. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, Rommens JM, Beaudet AL (1997) De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 15:74-77. CrossRef Medline.
38. Mulherkar SA, Jana NR (2010) Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome. Neurobiol Dis 40:586-592. CrossRef Medline.
39. Peters SU, Beaudet AL, Madduri N, Bacino CA (2004) Autism in Angelman syndrome: implications for autism research. Clin Genet 66:530-536.CrossRef Medline.
40. Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4:658–665. CrossRef Medline.
41. Qin Q, Baudry M, Liao G, Noniyev A, Galeano J, Bi X (2009) A novel function for p53: regulation of growth cone motility through interaction with Rho kinase. J Neurosci 29:5183–5192. CrossRef Medline.
42. Reith RM, Way S, McKenna J 3rd, Haines K, Gambello MJ (2011) Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis 43:113–122. CrossRef Medline.
43. Reith RM, McKenna J, Wu H, Hashmi SS, Cho SH, Dash PK, Gambello MJ (2013) Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol Dis 51:93–103. CrossRef Medline.
44. Rothwell PE, Fuccillo MV, Maxeiner S, Hayton SJ, Gokce O, Lim BK, Fowler SC, Malenka RC, Su¨dhof TC (2014) Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors. Cell 158:198-212. CrossRef Medline.
45. Schmidt A, Bickle M, Beck T, Hall MN (1997) The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 88:531–542. CrossRef Medline.
46. Smith SE, Zhou YD, Zhang G, Jin Z, Stoppel DC, Anderson MP (2011)Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice. Sci Transl Med 3:103ra197.CrossRef Medline.
47. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC (2010) mTOR Ser-2481 autophosphorylation monitors mTORCspecific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285:7866-7879. CrossRef Medline.
48. Thomanetz V, Angliker N, Cloetta D, Lustenberger RM, Schweighauser M, Oliveri F, Suzuki N, Ruegg MA (2013) Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology. J Cell Biol 201:293–308. CrossRef Medline.
49. Tsai PT, Hull C, Chu Y, Greene-Colozzi E, Sadowski AR, Leech JM, Steinberg J, Crawley JN, Regehr WG, Sahin M (2012) Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 488:647–651. CrossRef Medline.
50. van Woerden GM, Harris KD, Hojjati MR, Gustin RM, Qiu S, de Avila Freire R, Jiang YH, Elgersma Y, Weeber EJ (2007) Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci 10:280-282. CrossRef Medline.
51. Wang Y, Zhu G, Briz V, Hsu YT, Bi X, Baudry M (2014) A molecular brake controls the magnitude of long-term potentiation. Nat Commun 5:3051.CrossRef Medline.
52. Weeber EJ, Jiang YH, Elgersma Y, Varga AW, Carrasquillo Y, Brown SE, Christian JM, Mirnikjoo B, Silva A, Beaudet AL, Sweatt JD (2003) Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neurosci 23:2634-2644. Medline.
53. White JJ, Sillitoe RV (2013) Development of the cerebellum: from gene expression patterns to circuit maps. Wiley Interdiscip Rev Dev Biol 2:149–164. CrossRef Medline.
54. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471-484. CrossRef Medline.
55. Zheng L, Ding H, Lu Z, Li Y, Pan Y, Ning T, Ke Y (2008) E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells 13:285–294. CrossRef Medline.
56. Zhou HY, Huang SL (2012) Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer 31:8-18.CrossRef Medline.